AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01179789 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Argan oil
Description: Product should be administrated orally, 25 ml once daily or during the day with a meal (bread, salad ...) and a large glass of water
Study NCT01361113 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pazopanib
Description: 800 mg orally once daily for 8 weeks, prior to nephrectomy
Study NCT02548923 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: comparison to propofol
Study NCT00894244 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency device
Description: One treatment pass on one arm. 2-5 treatment passes on the other
Study NCT01237327 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Megestrol acetate
Description: Megestrol Acetate 160 mg oral tablets Qd
Study NCT01237327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exemestane (Aromasin)
Description: exemestane (Aromasin) 25 mg oral tablets Qd
Study NCT03205098 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood analysis
Description: Blood test of biological markers of mesenteric ischemia
Study NCT00070213 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX regimen
Study NCT00070213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX regimen
Study NCT00070213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Study NCT00070213 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorouracil
Study NCT00070213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Study NCT00070213 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leucovorin calcium
Study NCT00070213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Study NCT00070213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Study NCT00070213 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Study NCT00070213 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Study NCT00106639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: 15 mg twice daily
Study NCT00106639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: 30 mg twice daily
Study NCT00106639 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus
Description: dose adjusted according to level
Study NCT02769936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-cycloserine
Description: 100 mg D-cycloserine administered orally as encapsulated pill
Study NCT02769936 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered orally as encapsulated pill
Study NCT03296020 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HONEY
Description: 100% Natural pure Honey, produced by EIN HAROD CO-OPERATIVE, ISRAEL
Study NCT03013608 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Simple relocation of the nail plate in nailbed injuries in paediatric population
Description: Repositioning the nail bed without sutures
Study NCT03933722 — intervention group
Intervention type: DEVICE
Intervention: Caretaker
Description: Application of Caretaker device to subjects that have septic shock and that have an invasive arterial pressure monitor placed.
Study NCT03941197 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ready and Healthy for Kindergarten Family Literacy program
Description: Participants will participate in 8 parent-child health-themed literacy workshops. Participants will receive 2-3 text messages per week for 8 weeks.
Study NCT00752869 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dutasteride
Description: 0.5mg by mouth one time per day for 1 year
Study NCT00752869 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: one tablet per day for 1 year
Study NCT02919007 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silk'n HST treatment
Description: Intervention includes treatment with the Silk'n HST on the periorbital areas as instructed in the user's manual
Study NCT04108949 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tuning in to Kids
Description: A psychosocial intervention focusing on emotion socialization and emotion coaching.
Study NCT04108949 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: See description included in arm/Group description.
Study NCT00701480 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: skin cleanser contained Hibiscus sabdariffa extract
Description: face washing 2-3 times/day
Study NCT00701480 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: marketed skin cleanser
Description: face washing 2-3 times/day
Study NCT03468452 — intervention group
Intervention type: OTHER
Intervention: extubation
Description: Time of extubation
Study NCT04065581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acarbose/Metformin FDC(BAY81-9783)
Description: Single dose: 50 mg acarbose/500 mg metformin tablet, oral
Study NCT04065581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucobay
Description: Single dose: 50 mg tablet, oral
Study NCT04065581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucophage
Description: Single dose: 500 mg tablet, oral
Study NCT00258362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Dose = Area-under-the-curve 6 on Day 1 every 3 weeks for 3 cycles.
Study NCT00258362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: 75 mg/m\^2 on Day 1 of each course
Study NCT00258362 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Weekly, 5 days/week over 6-7 weeks (tailored 4500 cGy)
Study NCT02869815 — intervention group
Intervention type: PROCEDURE
Intervention: ICG+Methylene Blue
Description: ICG+Methylene Blue Arm:~One ml of methylene blue (1%) would be in injected sub-areolarly 5 minutes before surgery, and 1ml of ICG (0.125%) in the same site 3 minutes later. Massage of the breast would be applied to facilitate the movement of the tracers. A small incision would be made in the axilla, and a special device would be used to search the light nodes. During the sampling, blue nodes would also be resected . After the completion of SLNB, complete axillary dissection would be carried out.
Study NCT01458080 — intervention group
Intervention type: DRUG
Intervention: eltrombopag
Description: eltrombopag
Study NCT02721433 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pamidronate
Description: Bone-targeted agent as standard of care
Study NCT02721433 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab
Description: Bone-targeted agent as standard of care
Study NCT02721433 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronate
Description: Bone-targeted agent as standard of care
Study NCT04036253 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Erythropoietin alfa
Description: Prefilled syringes of erythropoietin
Study NCT01994902 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast test product
Description: The Coloplast test product is a newly developed ostomy appliance
Study NCT01994902 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SenSura Convex Light
Description: The comparator product is SenSura Convex Light, which is CE-marked and commercially available.
Study NCT01256385 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Given IV
Study NCT04036253 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Erythropoietin alfa
Description: Prefilled syringes of erythropoietin
Study NCT03068793 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Electroencephalography (EEG) and Magnetic Resonance Imaging (MRI)
Description: We will use these techniques combined with tests of reward anticipation and clinical interviews to explore connections between these measures and activity in the brain in patients with a diagnosis of schizophrenia, major depressive disorder, gambling disorder, or post traumatic stress disorder and healthy controls.
Study NCT00870532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral vinorelbine
Description: The patients will be divided into 3 cohorts (15 patients per cohort), each cohort receiving a fixed metronomic (thrice a week) dose of oral vinorelbine at 60 mg/week, 90 mg/week, and 120 mg/week respectively. We should arrive at 3 different MTDs from the 3 cohorts.
Study NCT00870532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib
Description: Each patient within each cohort will receive a starting dose of sorafenib at 200 mg bid for 4 weeks. In the absence of dose-limiting toxicities, the dose of sorafenib will be escalated to 400 mg bid for another 4 weeks, 600 mg bid for 4 weeks and then finally 800 mg bid. We should arrive at 3 different MTDs from the 3 cohorts.
Study NCT00917462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib, administered orally
Description: Sorafenib 400 mg twice daily administered continuously. Patients will continue on treatment until progression of disease. Each cycle consists of 28 days. The cycle start date will coincide with the physician visit date. Because of the potential need for physician visit scheduling to vary (due to both physician and patient issues), to avoid violation of, and deviation from, the protocol, these visits may vary by up to one to fourteen (1-14) days. A study diary will be completed by patients to ensure compliance with the study drug.
Study NCT00917462 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT/MRI
Description: A CT (computerized tomography) or MRI (magnetic resonance imaging) scan of the chest and abdomen will be obtained at baseline, after the first four weeks of therapy, at eight weeks, and then every eight weeks there afterwith a scheduling window of up to one to fourteen (1-14) days. The same imaging modality performed at baseline (CT or MRI) will be repeated at subsequent imaging.
Study NCT02176382 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: denosumab
Description: denosumab subcutaneous injection
Study NCT02176382 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: teriparatide
Description: teriparatide daily subcutaneous injection
Study NCT02176382 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic acid
Description: zoledronic acid infusion
Study NCT01256385 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01256385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Given IV
Study NCT02897063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Droxidopa
Description: Single oral dose 300 mg
Study NCT02897063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine
Description: Single oral dose 10 mg
Study NCT02897063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: sugar pill
Study NCT03631654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivabradine
Description: Ivabradine administration--tablets given 5 mg twice daily for 2 weeks, then 7.5 mg twice daily
Study NCT03631654 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo
Study NCT03215407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intra-articular Tocilizumab
Description: Patients will be randomly chosen to be intra-articular injected of tocilizumab injection
Study NCT03215407 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intra-articular Compound Betamethasone
Description: Patients will be randomly chosen to be intra-articular injected of compound betamethasone injection
Study NCT02243046 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control toothpaste
Description: 1450 ppm fluoride toothpaste control - Subjects will brush their whole mouth with the control toothpaste 2 times/day for 1 minute each time and rinse with water after brushing. This daily brushing routine will continue for the six (6) month study.
Study NCT02243046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental toothpaste
Description: 1450 ppm sodium fluoride/zinc base toothpaste - Subjects will brush their whole mouth with a fluoride/zinc toothpaste 2 times/day for 1 minute each time and rinse with water after brushing. This daily brushing routine will continue for the six (6) month study.
Study NCT02243046 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator
Description: 1450 ppm sodium fluoride/triclosan toothpaste - Subjects will brush their whole mouth with this toothpaste 2 times/day for 1 minute each time and rinse with water after brushing. This daily brushing routine will continue for the six (6) month study.
Study NCT04170244 — intervention group
Intervention type: OTHER
Intervention: AD subject visit sampling procedures
Description: Skin swabs for microbial analysis, Tape stripping and transepidermal water loss measurements (TEWL) with tape stripping (all patients) to assess skin barrier function, blood serum (adults \& optional for adolescents), and optional biopsy (adults only)
Study NCT04170244 — intervention group
Intervention type: OTHER
Intervention: PS subject visit sampling procedures
Description: Skin swabs for microbial analysis, Tape stripping and transepidermal water loss measurements (TEWL) with tape stripping (all patients) to assess skin barrier function, and blood serum (optional for all PS subjects)
Study NCT04170244 — intervention group
Intervention type: OTHER
Intervention: Healthy control visit sampling procedures
Description: Skin swabs for microbial analysis, Tape stripping and transepidermal water loss measurements (TEWL) with tape stripping (all patients) to assess skin barrier function, blood serum (adults \& optional for adolescents), and optional biopsy (adults only)
Study NCT01342172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Patients will receive gemcitabine 1000 mg/m2 IV on days 1 + 8 and cisplatin 70 mg/m2 IV on day 1 of each 21 day cycle. Lenalidomide will be given orally on days 1-14 and the dose will be escalated in successive cohorts during the phase Ib portion to define the recommended phase II dose. Patients will continue gemcitabine, cisplatin, plus lenalidomide for up to 6 cycles, in the absence of disease progression or prohibitive toxicity. After completion of 6 cycles of therapy, patients who have achieved at least stable disease will proceed with maintenance lenalidomide given orally on days 1-21 of each 28-day cycle. Treatment will continue, in the absence of prohibitive toxicity, until the time of disease progression.
Study NCT04246645 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CORE STABILITY EXERCISES
Description: SELECTED CORE EXERCISES
Study NCT01303640 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biolimus-eluting stent
Description: Biolimus-eluting stent
Study NCT01303640 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus-eluting stent
Description: Everolimus-eluting stent
Study NCT03704116 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Expedition
Description: On a laptop computer participants work on simulated daily life activities including packing for a trip, navigating a transit system, and learning at museum attractions. The intervention increases difficulty as participants accomplish goals. We are testing the effects of this performance challenge on executive function measures.
Study NCT03704116 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Expedition
Description: On a laptop computer participants work on simulated daily life activities including packing for a trip, navigating a transit system, and learning at museum attractions. The intervention increases difficulty as participants accomplish goals. We are testing the effects of this performance challenge on executive function measures.
Study NCT02616718 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Repeated computed tomography scan of abdomen
Description: Repeated computed tomography scan of abdomen within two weeks prior to surgery or 28-32 weeks after initial scan
Study NCT01362517 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quinvaxem
Description: A single dose (0.5 mL) of Quinvaxem contains:~diphtheria antitoxin (>= 30 IU), tetanus antitoxin (>= 60 IU), whole-cell inactive pertussis bacteria (>= 4 IU), 10 mcg Hib oligosaccharide conjugate (approx. 25 mcg CRM197), 10 mcg Hepatitis B surface antigen~One dose of Quinvaxem given at 2, 3 and 4 months of age
Study NCT04475237 — intervention group
Intervention type: OTHER
Intervention: CT-scan evaluation and segmentation
Description: CT-scans will be evaluated (to see if they are included in the research group) and segmented if they are accepted.
Study NCT00507832 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pimecrolimus
Description: twice daily topical
Study NCT00507832 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: twice daily topical
Study NCT00507832 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pimecrolimus
Description: topical application as a cream twice daily
Study NCT01487213 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Home self assessment of complete medical abortion
Description: Self assessment of complete abortion using a home semiquantitative U-hCG test. Follow-up out patient review two-three weeks later by qualified practitioner to evaluate success of procedure using the clinic's standard routine. The patient charts will be reviewed after three months in order to control for possible extra visits related to abortion-related complications.
Study NCT00310076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Description: Patients will receive thalidomide orally each evening for 24 months or until tumor progression is detected.
Study NCT00310076 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Description: Cytoreductive Surgery with Intraperitoneal Hyperthermic Chemotherapy
Study NCT01575041 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sodium
Description: Sodium Chloride (provided by Microz, Geleen, Netherlands): 8 capsules per day which equals a sodium intake of 3 grams.
Study NCT01575041 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sodium
Description: Sodium Chloride (provided by Microz, Geleen, Netherlands): 8 capsules per day which equals a sodium intake of 3 grams.
Study NCT01575041 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Potassium
Description: Potassium Chloride (provided by Microz, Geleen, Netherlands): 8 capsules per day which equals a potassium intake of 3 grams.
Study NCT01575041 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (cellulose, provided by Microz, Geleen, Netherlands): 8 capsules per day.
Study NCT04310475 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality assisted CBT
Description: This study uses virtual reality technology to assist cognitive behavioural therapy for social difficulties in people with first episode psychosis.
Study NCT01724801 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: whole brain radiation(WBI)
Description: WBI (30Gy/3Gy/10 fractions) plus concurrent or sequential chemotherapy for 4-6 cycles
Study NCT01724801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib
Description: administered orally at a dose of 125 mg 3 times daily
Study NCT02628509 — intervention group
Intervention type: DEVICE
Intervention: cardiac devices
Description: patients receiving mechanical circulatory support or undergoing trans aortic valve replacement
Study NCT02224183 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Individuals randomized to the education group will receive The Back Pain Helpbook, an educational book with strategies for self-care including an exercise program, lifestyle modification, and tips for managing flare-ups. In addition, they will receive an assignment sheet outlining specific chapters to read over the course of the 12-weeks. In addition, participants receive at 3, 6, 9, and 12 weeks newsletters highlighting main points from the assigned chapters.
Study NCT02224183 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Yoga
Description: Weekly yoga classes will each be taught by two yoga instructors. Classes will be 75 minutes long. Mats and props will be provided. Yoga participants will be encouraged to practice for 30 minutes on days when they do not have class. They will be provided free of charge with a participant handbook, mat, block, and strap to aid home practice. Yoga home practice videos will be placed online for home practice and the website will track time spent using the videos for home practice. DVDs will be provided for those that do not have consistent access to the internet at home.
Study NCT00935714 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Study NCT04474613 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Liquid biopsy
Description: Liquid biopsy done on a blood draw, taking approximately 7 days